“So we'll start to see some of that expense start to titrate into next year.”

In context

“o grow earnings over time. I’m not going to say whether that’s 2023 yet or not. And with respect to operating margins, specifically, what we’ve said is we look to be at the high end of our medtech peer set. And by medtech, that means high-growth companies that have growth opportunities as we see that we do. I'll speak to – for a second on SG&A. We do have some infrastructure that is either needs to be built out to support the growth particularly in manufacturing or we have some processes in IT and in other parts of the business where we're long lived on our pavement and there's some repaving or potholes to fix that we will finish. We do expect to see highly targeted spending in that area going forward. And as we retire, some of that project spend will be thoughtful about where we go next. So we'll start to see some of that expense start to titrate into next year. Amit Hazan: Thank you. Operator: Okay. Next in the line of Travis Steed with Bank of America. Please go ahead. Travis Steed: All right. Thanks for taking the questions. Gary, I'd love a little more color just on the overall hospital capital environment. Are you seeing hospitals just being more cautious on the near term or do you think we're in for a longer duration CapEx, slowdown? I'm curious how you think the slowdown could range in terms of outcomes, if it's like, 2008, 2009 or 2013, 2014 or 2020 and also like leases ticked up to 42% this quarter, I'm curious where you think that could peak in the slower CapEx environment? Gary Guthart: Yeah. Hard to predict the depth in duration of hospital pressure. So I won't, I will talk about what the – I think what the inputs are, what they're fa”